Hematology-Oncology | sciencenewsnet.in

Breaking News

Potential of ginsenoside Rg1 to treat aplastic anemia via mitogen activated protein kinase pathway in cyclophosphamide-induced myelosuppression mouse model

Refining adipose-derived stem cell isolation for optimal regenerative therapy

Resilience and challenges: Evaluating the impact of stress conditions on mesenchymal stem cells across different passages

Melatonin-based priming of stem cells to alleviate oxidative stress

Effects of miR-214-5p and miR-21-5p in hypoxic endometrial epithelial-cell-derived exosomes on human umbilical cord mesenchymal stem cells

Efficacy of serum-free cultured human umbilical cord mesenchymal stem cells in the treatment of knee osteoarthritis in mice

Exosome-based strategy against colon cancer using small interfering RNA-loaded vesicles targeting soluble a proliferation-inducing ligand

Yes-associated protein-mediated melatonin regulates the function of periodontal ligament stem cells under oxidative stress conditions

Can We Avert the Looming Food Crisis of Climate Change?

Embedding Owner-Manager Values in the Small and Medium Sized Enterprise Context: A Lockean Conceptualisation

26 Nov, 2024

UTSW’s Simmons Cancer Center awarded more than $11.5 million in CPRIT funding

September 6, 2024 sarah JonasAnnouncement

Eight scientists and physicians in the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern have been awarded more than $11.5 million in grants from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the state’s fight against cancer.

Widespread disparities exist in treating advanced cancers

September 4, 2024 sarah JonasResearch Results

A study led by researchers at UT Southwestern Medical Center reveals significant disparities across the country in the use of immunotherapy for patients with advanced kidney and bladder cancers.

Drug targeting clear cell renal cell carcinoma shows promising approach

April 23, 2024 sarah JonasResearch Results

In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC). Published in Clinical Cancer Research, the findings illustrate the potential of siRNA for cancer therapy.